Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies

Sridhar Mani, Nicholas J. Vogelzang, Donna Bertucci, Walter M. Stadler, Richard L. Schilsky, Mark J. Ratain

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

BACKGROUND. The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil. PATIENTS AND METHODS. Eligible patients with advanced solid tumors received escalating doses of gemcitabine 200 and 300 mg/m2 weekly as a 30-minute infusion on Days 1, 8, and 15 every 4 weeks (schedule 1) or 450, 600, 800, 1000, 1250, 1500, 1800, and 2200 mg/m2 on Days 1 and 8 (schedule 2) every 3 weeks, respectively. At the completion of gemcitabine infusion (Day 1), patients received fixed dose continuous infusion of 5-fluorouracil at either 300 mg/m2 (Days 1-21) or 200 mg/m2 (Days 1-21; schedule 1) every 4 weeks or 200 mg/m2 (Days 1-14; schedule 2] every 3 weeks, respectively. Toxicity assessments were performed weekly on study, and efficacy measurements were performed every 6-8 weeks. RESULTS. Seventy patients with advanced solid malignancies received a total of 220 cycles of combination chemotherapy. Eleven (14.3%) patients received no more than 1 treatment cycle of combination therapy. Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m2/week when combined with 5-fluorouracil (5-FU) at 200 mg/m2/day (Days 1-21) repeated every 4 weeks. The schedule 2 maximum tolerated dose of gemcitabine was 2200 mg/m2/week when combined with 5-FU dosed at 200 mg/m2/day (Days 1-14) repeated every 3 weeks. In schedule 1, the limiting factor for gemcitabine delivery was the Day 15 dose that often was omitted because of myelosuppression and/or mucositis. In schedule 1 cycle 1, nonhematologic toxicity was common and included Grade 3-4 toxicities: mucositis (8 patients), fatigue (2 patients), and anorexia (1 patient). One patient had Grade 3-4 neutropenia at dose level 5 (maximum tolerated dose). In schedule 2 cycle 1, hematologic toxicities were more common than nonhematologic toxicity and included Grade 3 anemia (3 patients), Grade 3 neutropenia (4 patients), and Grade 3 thrombocytopenia (2 patients). The nonhematologic toxicities included Grade 3 mucositis (3 patients), Grade 3 fatigue (2 patients), and Grade 3 dehydration (1 patient). Overall, antitumor activity was observed in seven patients. Three of 30 patients with cytokine refractory renal cell carcinoma (RCC; relative risk [RR] 10 %; 95% confidence interval [CI], 0.82-22%) had a partial response. Of the remaining 27 patients with RCC, 4 patients had a minor response, and 10 patients had stable disease lasting a median of 6.4 (range, 4-12) months. The remaining 5 responses occurred in 40 patients (RR, 12.5%; 95% CI, 4.2-26.8%): 2 patients with 5-FU refractory colon carcinoma, 1 patient with hepatoma, 1 patient with paclitaxel-cisplatin-resistant ovarian carcinoma, and 1 patient with cisplatin-resistant head and neck squamous cell carcinoma had a partial response. CONCLUSIONS. For Phase II development, gemcitabine 450-600 mg/m2 on Days 1, 8, and 15 can be safely combined with 5-FU 200 mg/m2 given as a continuous infusion (Days 1-21) of a 28-day cycle or gemcitabine 1800 mg/m2 Days 1 and 8 given with 5-FU 200 mg/m2 as a continuous infusion (Days 1-14) of a 21-day cycle. The observed antitumor activity in several solid tumors, especially in renal cell carcinoma, warrants broad Phase II evaluation.

Original languageEnglish (US)
Pages (from-to)1567-1576
Number of pages10
JournalCancer
Volume92
Issue number6
DOIs
StatePublished - Sep 15 2001
Externally publishedYes

Fingerprint

gemcitabine
Fluorouracil
Neoplasms
Appointments and Schedules
Maximum Tolerated Dose
Mucositis

Keywords

  • 5-fluorouracil
  • Continuous infusion
  • Gemcitabine
  • Maximum tolerated dose
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies. / Mani, Sridhar; Vogelzang, Nicholas J.; Bertucci, Donna; Stadler, Walter M.; Schilsky, Richard L.; Ratain, Mark J.

In: Cancer, Vol. 92, No. 6, 15.09.2001, p. 1567-1576.

Research output: Contribution to journalArticle

@article{1c041a7dd79a46ee84387592befbe52d,
title = "Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies",
abstract = "BACKGROUND. The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil. PATIENTS AND METHODS. Eligible patients with advanced solid tumors received escalating doses of gemcitabine 200 and 300 mg/m2 weekly as a 30-minute infusion on Days 1, 8, and 15 every 4 weeks (schedule 1) or 450, 600, 800, 1000, 1250, 1500, 1800, and 2200 mg/m2 on Days 1 and 8 (schedule 2) every 3 weeks, respectively. At the completion of gemcitabine infusion (Day 1), patients received fixed dose continuous infusion of 5-fluorouracil at either 300 mg/m2 (Days 1-21) or 200 mg/m2 (Days 1-21; schedule 1) every 4 weeks or 200 mg/m2 (Days 1-14; schedule 2] every 3 weeks, respectively. Toxicity assessments were performed weekly on study, and efficacy measurements were performed every 6-8 weeks. RESULTS. Seventy patients with advanced solid malignancies received a total of 220 cycles of combination chemotherapy. Eleven (14.3{\%}) patients received no more than 1 treatment cycle of combination therapy. Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m2/week when combined with 5-fluorouracil (5-FU) at 200 mg/m2/day (Days 1-21) repeated every 4 weeks. The schedule 2 maximum tolerated dose of gemcitabine was 2200 mg/m2/week when combined with 5-FU dosed at 200 mg/m2/day (Days 1-14) repeated every 3 weeks. In schedule 1, the limiting factor for gemcitabine delivery was the Day 15 dose that often was omitted because of myelosuppression and/or mucositis. In schedule 1 cycle 1, nonhematologic toxicity was common and included Grade 3-4 toxicities: mucositis (8 patients), fatigue (2 patients), and anorexia (1 patient). One patient had Grade 3-4 neutropenia at dose level 5 (maximum tolerated dose). In schedule 2 cycle 1, hematologic toxicities were more common than nonhematologic toxicity and included Grade 3 anemia (3 patients), Grade 3 neutropenia (4 patients), and Grade 3 thrombocytopenia (2 patients). The nonhematologic toxicities included Grade 3 mucositis (3 patients), Grade 3 fatigue (2 patients), and Grade 3 dehydration (1 patient). Overall, antitumor activity was observed in seven patients. Three of 30 patients with cytokine refractory renal cell carcinoma (RCC; relative risk [RR] 10 {\%}; 95{\%} confidence interval [CI], 0.82-22{\%}) had a partial response. Of the remaining 27 patients with RCC, 4 patients had a minor response, and 10 patients had stable disease lasting a median of 6.4 (range, 4-12) months. The remaining 5 responses occurred in 40 patients (RR, 12.5{\%}; 95{\%} CI, 4.2-26.8{\%}): 2 patients with 5-FU refractory colon carcinoma, 1 patient with hepatoma, 1 patient with paclitaxel-cisplatin-resistant ovarian carcinoma, and 1 patient with cisplatin-resistant head and neck squamous cell carcinoma had a partial response. CONCLUSIONS. For Phase II development, gemcitabine 450-600 mg/m2 on Days 1, 8, and 15 can be safely combined with 5-FU 200 mg/m2 given as a continuous infusion (Days 1-21) of a 28-day cycle or gemcitabine 1800 mg/m2 Days 1 and 8 given with 5-FU 200 mg/m2 as a continuous infusion (Days 1-14) of a 21-day cycle. The observed antitumor activity in several solid tumors, especially in renal cell carcinoma, warrants broad Phase II evaluation.",
keywords = "5-fluorouracil, Continuous infusion, Gemcitabine, Maximum tolerated dose, Phase I",
author = "Sridhar Mani and Vogelzang, {Nicholas J.} and Donna Bertucci and Stadler, {Walter M.} and Schilsky, {Richard L.} and Ratain, {Mark J.}",
year = "2001",
month = "9",
day = "15",
doi = "10.1002/1097-0142(20010915)92:6<1567::AID-CNCR1483>3.0.CO;2-L",
language = "English (US)",
volume = "92",
pages = "1567--1576",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors

T2 - A potential broadly active regimen for advanced solid tumor malignancies

AU - Mani, Sridhar

AU - Vogelzang, Nicholas J.

AU - Bertucci, Donna

AU - Stadler, Walter M.

AU - Schilsky, Richard L.

AU - Ratain, Mark J.

PY - 2001/9/15

Y1 - 2001/9/15

N2 - BACKGROUND. The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil. PATIENTS AND METHODS. Eligible patients with advanced solid tumors received escalating doses of gemcitabine 200 and 300 mg/m2 weekly as a 30-minute infusion on Days 1, 8, and 15 every 4 weeks (schedule 1) or 450, 600, 800, 1000, 1250, 1500, 1800, and 2200 mg/m2 on Days 1 and 8 (schedule 2) every 3 weeks, respectively. At the completion of gemcitabine infusion (Day 1), patients received fixed dose continuous infusion of 5-fluorouracil at either 300 mg/m2 (Days 1-21) or 200 mg/m2 (Days 1-21; schedule 1) every 4 weeks or 200 mg/m2 (Days 1-14; schedule 2] every 3 weeks, respectively. Toxicity assessments were performed weekly on study, and efficacy measurements were performed every 6-8 weeks. RESULTS. Seventy patients with advanced solid malignancies received a total of 220 cycles of combination chemotherapy. Eleven (14.3%) patients received no more than 1 treatment cycle of combination therapy. Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m2/week when combined with 5-fluorouracil (5-FU) at 200 mg/m2/day (Days 1-21) repeated every 4 weeks. The schedule 2 maximum tolerated dose of gemcitabine was 2200 mg/m2/week when combined with 5-FU dosed at 200 mg/m2/day (Days 1-14) repeated every 3 weeks. In schedule 1, the limiting factor for gemcitabine delivery was the Day 15 dose that often was omitted because of myelosuppression and/or mucositis. In schedule 1 cycle 1, nonhematologic toxicity was common and included Grade 3-4 toxicities: mucositis (8 patients), fatigue (2 patients), and anorexia (1 patient). One patient had Grade 3-4 neutropenia at dose level 5 (maximum tolerated dose). In schedule 2 cycle 1, hematologic toxicities were more common than nonhematologic toxicity and included Grade 3 anemia (3 patients), Grade 3 neutropenia (4 patients), and Grade 3 thrombocytopenia (2 patients). The nonhematologic toxicities included Grade 3 mucositis (3 patients), Grade 3 fatigue (2 patients), and Grade 3 dehydration (1 patient). Overall, antitumor activity was observed in seven patients. Three of 30 patients with cytokine refractory renal cell carcinoma (RCC; relative risk [RR] 10 %; 95% confidence interval [CI], 0.82-22%) had a partial response. Of the remaining 27 patients with RCC, 4 patients had a minor response, and 10 patients had stable disease lasting a median of 6.4 (range, 4-12) months. The remaining 5 responses occurred in 40 patients (RR, 12.5%; 95% CI, 4.2-26.8%): 2 patients with 5-FU refractory colon carcinoma, 1 patient with hepatoma, 1 patient with paclitaxel-cisplatin-resistant ovarian carcinoma, and 1 patient with cisplatin-resistant head and neck squamous cell carcinoma had a partial response. CONCLUSIONS. For Phase II development, gemcitabine 450-600 mg/m2 on Days 1, 8, and 15 can be safely combined with 5-FU 200 mg/m2 given as a continuous infusion (Days 1-21) of a 28-day cycle or gemcitabine 1800 mg/m2 Days 1 and 8 given with 5-FU 200 mg/m2 as a continuous infusion (Days 1-14) of a 21-day cycle. The observed antitumor activity in several solid tumors, especially in renal cell carcinoma, warrants broad Phase II evaluation.

AB - BACKGROUND. The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil. PATIENTS AND METHODS. Eligible patients with advanced solid tumors received escalating doses of gemcitabine 200 and 300 mg/m2 weekly as a 30-minute infusion on Days 1, 8, and 15 every 4 weeks (schedule 1) or 450, 600, 800, 1000, 1250, 1500, 1800, and 2200 mg/m2 on Days 1 and 8 (schedule 2) every 3 weeks, respectively. At the completion of gemcitabine infusion (Day 1), patients received fixed dose continuous infusion of 5-fluorouracil at either 300 mg/m2 (Days 1-21) or 200 mg/m2 (Days 1-21; schedule 1) every 4 weeks or 200 mg/m2 (Days 1-14; schedule 2] every 3 weeks, respectively. Toxicity assessments were performed weekly on study, and efficacy measurements were performed every 6-8 weeks. RESULTS. Seventy patients with advanced solid malignancies received a total of 220 cycles of combination chemotherapy. Eleven (14.3%) patients received no more than 1 treatment cycle of combination therapy. Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m2/week when combined with 5-fluorouracil (5-FU) at 200 mg/m2/day (Days 1-21) repeated every 4 weeks. The schedule 2 maximum tolerated dose of gemcitabine was 2200 mg/m2/week when combined with 5-FU dosed at 200 mg/m2/day (Days 1-14) repeated every 3 weeks. In schedule 1, the limiting factor for gemcitabine delivery was the Day 15 dose that often was omitted because of myelosuppression and/or mucositis. In schedule 1 cycle 1, nonhematologic toxicity was common and included Grade 3-4 toxicities: mucositis (8 patients), fatigue (2 patients), and anorexia (1 patient). One patient had Grade 3-4 neutropenia at dose level 5 (maximum tolerated dose). In schedule 2 cycle 1, hematologic toxicities were more common than nonhematologic toxicity and included Grade 3 anemia (3 patients), Grade 3 neutropenia (4 patients), and Grade 3 thrombocytopenia (2 patients). The nonhematologic toxicities included Grade 3 mucositis (3 patients), Grade 3 fatigue (2 patients), and Grade 3 dehydration (1 patient). Overall, antitumor activity was observed in seven patients. Three of 30 patients with cytokine refractory renal cell carcinoma (RCC; relative risk [RR] 10 %; 95% confidence interval [CI], 0.82-22%) had a partial response. Of the remaining 27 patients with RCC, 4 patients had a minor response, and 10 patients had stable disease lasting a median of 6.4 (range, 4-12) months. The remaining 5 responses occurred in 40 patients (RR, 12.5%; 95% CI, 4.2-26.8%): 2 patients with 5-FU refractory colon carcinoma, 1 patient with hepatoma, 1 patient with paclitaxel-cisplatin-resistant ovarian carcinoma, and 1 patient with cisplatin-resistant head and neck squamous cell carcinoma had a partial response. CONCLUSIONS. For Phase II development, gemcitabine 450-600 mg/m2 on Days 1, 8, and 15 can be safely combined with 5-FU 200 mg/m2 given as a continuous infusion (Days 1-21) of a 28-day cycle or gemcitabine 1800 mg/m2 Days 1 and 8 given with 5-FU 200 mg/m2 as a continuous infusion (Days 1-14) of a 21-day cycle. The observed antitumor activity in several solid tumors, especially in renal cell carcinoma, warrants broad Phase II evaluation.

KW - 5-fluorouracil

KW - Continuous infusion

KW - Gemcitabine

KW - Maximum tolerated dose

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0035883565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035883565&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010915)92:6<1567::AID-CNCR1483>3.0.CO;2-L

DO - 10.1002/1097-0142(20010915)92:6<1567::AID-CNCR1483>3.0.CO;2-L

M3 - Article

C2 - 11745236

AN - SCOPUS:0035883565

VL - 92

SP - 1567

EP - 1576

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -